Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance
Overview
US biopharma firm's Q3 ARCALYST revenue rose 58% yr/yr to $286 mln
Net income for Q3 more than doubled to $47.3 mln from $18.4 mln last year
Company raised 2026 ARCALYST revenue guidance to $1.045-$1.050 bln
Outlook
Kiniksa raises 2026 ARCALYST net product revenue guidance to $1.045-$1.050 bln
Company expects 2026 R&D expenses of $160-$170 mln and SG&A expenses of $270-$280 mln
Company expects to remain cash flow positive on an annual basis under current operating plan
Result Drivers
ARCALYST ADOPTION - Co said strong commercial execution led to gains in patient and physician adoption of ARCALYST for recurrent pericarditis
OPERATING EXPENSES - Co said higher operating expenses were mainly due to increased ARCALYST sales and investment in commercialization
R&D SPENDING - Co said increased R&D expenses were mainly due to higher KPL-387 clinical activity
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $285.97 mln | ||
Q3 EPS | $0.56 | ||
Q3 Net Income | $47.35 mln | ||
Q3 Operating Expenses | $231.73 mln | ||
Q3 Pretax Profit | $59.06 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $98.00, about 34.3% above its October 26 closing price of $72.98
The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 42 three months ago
Reuters Recommended Reads
Oct 27 - Nautilus Biotechnology Q3 revenue beats
Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss
Oct 24 - Amgen drug combined with immunotherapy extends survival in lung cancer trial
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)